172 related articles for article (PubMed ID: 38396056)
1. Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment.
Ding Q; Lin F; Huang Z; Li Y; Cai S; Chen X; Liu H; Qiu S
Sci Rep; 2024 Feb; 14(1):4426. PubMed ID: 38396056
[TBL] [Abstract][Full Text] [Related]
2. Non-coding RNA-mediated high expression of
Chen K; Gong S; Fang X; Li Q; Ye M; Li J; Huang S; Zhao Y; Liu N; Li Y; Ma J
Front Immunol; 2022; 13():920136. PubMed ID: 36159813
[TBL] [Abstract][Full Text] [Related]
3. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
Huang J; Liang B; Wang T
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
[TBL] [Abstract][Full Text] [Related]
4. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
Hu R; Lu M; She L
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
[TBL] [Abstract][Full Text] [Related]
7. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
8. Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.
Chen Y
Dis Markers; 2022; 2022():6410113. PubMed ID: 35756491
[TBL] [Abstract][Full Text] [Related]
9. CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma.
Li Z; Qiu X; He Q; Fu X; Ji F; Tian X
Sci Rep; 2023 Jul; 13(1):11831. PubMed ID: 37481637
[TBL] [Abstract][Full Text] [Related]
10. Multi-Omics Analyses to Identify FCGBP as a Potential Predictor in Head and Neck Squamous Cell Carcinoma.
Lin YH; Yang YF; Shiue YL
Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626334
[TBL] [Abstract][Full Text] [Related]
11. FCGBP Is a Promising Prognostic Biomarker and Correlates with Immunotherapy Efficacy in Oral Squamous Cell Carcinoma.
Shen T; Zhang J; Wang Y; Liu B
J Immunol Res; 2022; 2022():8443392. PubMed ID: 35733916
[TBL] [Abstract][Full Text] [Related]
12. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
13.
Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
[TBL] [Abstract][Full Text] [Related]
14. Biomarker Potential of
Ju Y; Zhu F; Fang B
Int J Med Sci; 2024; 21(5):921-936. PubMed ID: 38617010
[TBL] [Abstract][Full Text] [Related]
15. Investigating diagnostic potential of long non-coding RNAs in head and neck squamous cell carcinoma using TCGA database and clinical specimens.
Lan T; Yan Y; Zheng D; Ding L
Sci Rep; 2024 Mar; 14(1):7500. PubMed ID: 38553620
[TBL] [Abstract][Full Text] [Related]
16. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
Li Y; Liu H
Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
[TBL] [Abstract][Full Text] [Related]
17. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Shi Y; Huang J; Hu Y; Shen Y
BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359
[TBL] [Abstract][Full Text] [Related]
18. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
Huang C; Liu J
Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
[TBL] [Abstract][Full Text] [Related]
19. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
20. Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.
Hu C; Fan J; He G; Dong C; Zhou S; Zheng Y
PLoS One; 2022; 17(6):e0269166. PubMed ID: 35653344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
